Washed human unactivated platelets attached and spread on thrombospondin (TSP)-coated microtiter plates. Platelet adhesion was promoted by divalent cations Mn2", Mg2", and Ca2" as compared to buffer having all divalent cations complexed with EDTA. TSP-dependent adhesion was inhibited by anti-TSP fab fragments, an anti-TSP monoclonal antibody, an RGDcontaining peptide, complex-specific anti-glycoprotein (GP)IIb-IIIa monoclonal antibodies (A2A, or AP-2) and anti-VLA-2 monoclonal antibodies (6F1 and Gi9), but not by rabbit preimmune fab fragments, mouse IgG, an anti-GPIIIa monoclonal antibody, or monoclonal antibodies against either the human vitronectin receptor, glycocalicin, or GPIV. At saturating concentrations, anti-GPIIb-IIIa inhibited adhesion by 40-60%. Glanzman's thrombasthenic platelets, which lack GPIIbIIla, adhered to TSP to the same extent as anti-GPIIb-IIIatreated normal platelets or 40-60% as well as untreated normal platelets. Antibody 6F1 (5-10 gg/ml) inhibited platelet adhesion of both normal and thrombasthenic platelets by 84-100%. Both VLA-2 antibodies also inhibited collagen-induced platelet adhesion, but had no effect on fibronectin-induced adhesion of normal platelets. These data indicate that platelets specifically adhere to TSP and that this adhesion is mediated through GPIIb-IIIa and/or VLA-2. (J. Clin.
Introduction
Platelet adhesion is a critical step in the process of hemostasis. When a blood vessel is ruptured, a complex cascade ofevents is rapidly triggered in order to seal the damaged vessel and prevent further bleeding. Initially, platelets adhere to components of the injured vessel, become activated, secrete the contents of their granules, and quickly transform the area ofthe injury into a highly thrombogenic surface. Subsequently, the adherent layer of platelets activates and binds more platelets, forming platelet aggregates. The platelet aggregates are procoagulant, generating locally high concentrations of thrombin, and converting platelet-bound fibrinogen into fibrin. The growing platelet fibrin plug entraps other cells, such as erythrocytes, and the resulting thrombus rapidly seals the bleeding vessel. OKM5 , specific against platelet GPIV, were purchased from Amac, Inc., Westbrook, ME and Ortho Diagnostics Systems, Inc., Raritan, NJ, respectively. Polyclonal rabbit anti-human TSP antibody was raised against the 1 80,000-mol wt chain of purified TSP eluted from an SDS gel as previously described (5) . The antibody specifically recognized TSP as demonstrated by direct ELISA but did not cross-react with 200 ng ofthe following proteins immobilized on a microtiter dish: albumin, fibrinogen, fibronectin, collagen, and vitronectin. For example, there was no statistical difference in the reactivity of polyclonal anti-TSP IgG toward either albumin or vitronectin giving an absorbance value of 0.086±0.019 and 0.122±0.016, respectively. Fab fragments from anti-TSP and preimmune serum were prepared according to the instructions provided with a kit purchased from Pierce Chemical Co. Anti-human TSP (MAb 054) and anti-human collagen type IV (MAbl430) monoclonal antibodies were purchased from Chemicon, Temecula, CA. The commercially available MAb 054 is clone PlO developed and characterized by Clezardin et al. (12) . Human vitronectin, anti-vitronectin, fibronectin, and anti-fibronectin were obtained from Calbiochem-Behring Corp., La Jolla, CA. Biotin conjugated goat anti-rabbit Fab-specific IgG was obtained from Accurate Chemical and Scientific Corp., Westbury, NY.
Protein assay. Protein concentrations were determined by the BCA protein assay, adapted for microtiter plates, as described by the Pierce Chemical Co. Bovine serum albumin (BSA) was used as standard.
Platelet isolation. Blood (100 ml) was obtained by venipuncture from normal volunteers and anticoagulated with acid citrate dextrose (National Institutes of Health formula). Prostaglandin El (PGEI) was added to a final concentration of 1 MM. Platelet-rich-plasma (PRP) was prepared by centrifuging the blood at room temperature for 20 min at 150 g. Platelets were pelleted by centrifuging the PRP at room temperature for 20 min at 3,000g. The platelet pellet was then washed twice in resuspension buffer (Hepes-buffered Tyrode's solution, pH 6.5, containing 5 mM Hepes, 4 mM NaH2PO4, 137 mM NaCI, 2.6 mM KC1, 1 mM MgCl2, 5 mM glucose, 1 mg/ml BSA) containing 5.0 U/ml apyrase and centrifuged at room temperature for 20 min at 3,000 g and resuspended to a final concentration of I09 platelets/ml in platelet buffer (5.0 mM Hepes, pH 7.3, containing 140 mM NaCl and 1 mg/ml BSA).
Platelet ultrastructural studies. Washed platelets either unactivated or activated for 3 min with 1 U/ml thrombin were centrifuged gently at 3,000 g for 5 min and the pellets fixed by addition of 1 ml of 0.1 M phosphate buffer, pH 7.4, containing 4% formaldehyde and 1% glutaraldehyde, postfixed in OS04, dehydrated in graded ethanol, and embedded in Epon. Thin sections were prepared with an ultramicrotome (LKB III, LKB Instruments, Inc., Gaithersburg, MD), stained with methanolic uranyl acetate and lead citrate, and examined with a transmission electron microscope (model 1OA, Carl Zeiss, Inc., Thornwood, NY).
Platelet adhesion assay. The number of adherent platelets was essentially determined as previously described (13) . Briefly, 100 M1 of 5 x I08 platelets/ml were added to microtiter plates, the wells of which were pretreated overnight at 4°C with 50 Ml of a 40-Ag/ml protein solution prepared in platelet buffer or in 5 mM acetic acid for rat skin collagen, and the wells were blocked for 1 h with 1% BSA. Platelets were incubated in the wells for 30 min and nonadherent platelets were removed by aspiration and wells washed three times with 200 ,l of platelet buffer. The number of adherent platelets was determined by measuring the platelet-derived protein using the BCA protein assay. The number of adherent platelets was proportional to the platelet-derived protein as measured using the BCA protein assay.
Measurement of bound anti-TSP Fab fragments. labeled with 125I-labeled iodine using lodobeads as previously described (14) . Free iodide was removed from protein solutions by centrifugation through small Sephadex G25 columns equilibrated in platelet buffer as previously described (15) . Binding assays were performed as previously described (16 
Results
Purity ofTSPpreparations. To rule out the presence ofcontaminants in our TSP preparations that could contribute to the adhesive activity of TSP, TSP preparations were examined by direct ELISA for the presence of fibronectin, vitronectin, and collagen (Table I ). Consistent with our previous studies (6) , no fibronectin, vitronectin, or collagen was detected.
Ultrastructural analysis of platelets. To confirm that the platelets used in the adhesion study were not activated, platelets were fixed and processed for transmission electron microscopy. Two groups ofplatelets were compared, those used in our adhesion studies and a control group activated with 1 U/ml of thrombin ( Fig. 1 ). The electron micrographs in Fig. 1 showed that the platelets used in the adhesion studies showed no evidence of activation such as shape change or degranulation. In contrast, when activated with 1 U/ml of thrombin platelets were degranulated and irregular in shape (Fig. I B) . These results are consistent with the serotonin release studies and IgG binding studies described below indicating that the platelets used in this were not activated. Divalent cation requirements for TSP-induced platelet adhesion. TSP-induced platelet adhesion was divalent cation dependent (Table II) . Little or no platelet adhesion was observed in the presence of either buffer, or 1 mM EDTA. In contrast, platelet adhesion was observed in the presence of either Ca"2, Mg 2, or Mn 2. Maximal potentiation ofplatelet adhesion was observed in the presence of either 100 IAM Mn 2, 1 mM Ca 2, or 1 mM Mg+2. Mn+2 gave the greatest potentiation, showing a 3-and 10-fold stimulation over that observed in the presence of either Ca+2 or Mg+2, respectively. In contrast, platelet adhesion to fibrinogen was promoted to about the same extent by the three ions tested, whereas adhesion to fibronectin showed the same Mn+2 dependence as compared to TSP but revealed a higher Mg+2 sensitivity (Table II) . It is unlikely the effect of Mn+2 on TSP-induced platelet adhesion was due to platelet activation or exposure offibrinogen receptor sites but rather an increase in the affinity of the platelet receptor for TSP because of the following observations: (a) Mn+2 did not cause a significant increase in release of platelet serotonin as compared to buffer alone, whereas thrombin released 85% serotonin (Table  III) . (b) Mn+2 caused no increase over control buffer in plateletbound IgG, anti-GPIIb-IIIa (AP-2), or anti-VLA-2 (6F1) (Table IV). (c) Mn+2 caused a < 30% potentiation ofplatelet adhesion to fibrinogen as compared to that observed in the presence of either Mg+2 or Ca+2. If platelet activation and exposure of fibrinogen receptor sites were induced by Mn+2, then one might expect to see more Mn+2-potentiated fibrinogen-induced platelet adhesion than the 30% observed.
In summary, these results indicate that platelet adhesion to TSP is highly dependent on the presence and nature ofdivalent cations. The divalent cations Mn+2, Mg+2, and Ca+2 enhanced platelet adhesion to TSP by 84-, 9-, 25-fold, respectively, as compared to adhesion obtained in the absence of ions Platelets activated with 1 U/ml thrombin. Platelets were processed for electron microscopy as described in Methods. Note: The platelets in A are discoid and granulated. In contrast, the platelets in B are clumped and irregular and the majority are devoid of granules. X24,000. The number of adherent platelets was determined by measuring the platelet-derived protein using the BCA protein assay as previously described (13) . The data is presented as the mean of three replicates±SD.
EDTA). Since Mn"2 ion gave the greatest potentiation, all subsequent experiments were performed in the presence of 100 AM Mn+2. Effect ofanti-TSP Fabfragments and an anti-TSP monoclonal antibody on TSP-induced platelet adhesion. To establish the specificity of TSP-induced platelet adhesion, immobilized TSP or fibrinogen, a protein that was previously found to constitute < 0.01 % of our purified TSP preparations (5), were treated with anti-TSP Fab fragments or normal rabbit Fab fragments and evaluated for platelet adhesion and bound antibody (Fig. 2) . The results of this experiment showed that anti-TSP Fab fragments specifically bound to TSP and inhibited platelet adhesion to TSP-coated surfaces. No inhibition of adhesion was observed with fibrinogen-coated wells. Similar results were obtained with an anti-TSP monoclonal antibody which completely inhibited adhesion to TSP, but had no effect on platelet adhesion to collagen (Fig. 3) . These results indicate that platelet adhesion to TSP-coated wells is specific and not Effect ofanti-platelet monoclonal antibodies and an RGDcontaining peptide on TSP-induced platelet adhesion. To identify possible platelet receptors mediating TSP-induced platelet adhesion, platelets were incubated with various platelet monoclonal antibodies, and RGD-containing peptides and evaluated for their ability to adhere to TSP-coated microtiter wells (Table V) . Maximum inhibition (60-89%) was obtained with monoclonal antibodies against VLA-2, GPIIb-IIIa, and with GRGDS. Inhibition with monoclonal antibodies against VLA-2 and GPIIb-IIIa was dose dependent (Fig. 4) . However, antiGPIIb-IIIa monoclonal antibodies gave not > 50-60% inhibition even at saturating concentrations (> 50 Mg/ml) of antibody. These results suggest that platelet adhesion to TSP is partly mediated by GPIIb-IIIa, VLA-2, and other RGD-specific platelet adhesion receptors. mune Fab (designated preimmune Fab) or anti-TSP fragments (designated anti-TSP Fab) as described in Methods. The number of adherent platelets were determined by protein assay and the bound Fab fragments were determined from absorbance measurements by ELISA as described in Methods. The solid bars and cross-hatched bars represent platelet adhesion to TSP and fibrinogen, respectively. The open bar graphs represent the binding of Fab fragments to TSP-coated wells. Controls for platelet adhesion and Fab fragment binding were obtained from preimmune-treated wells and anti-TSP-treated wells, respectively. Note: Anti-TSP Fab fragments bound to TSP-coated wells, inhibited platelet adhesion to TSP-coated wells, but had no effect on platelet adhesion to fibrinogen-coated wells. Figure 3 . The effect of monoclonal anti-TSP on TSP-induced platelet adhesion. Platelet suspensions (100 Ml of 5 x 108 platelets/ ml) were incubated for 30 min in the wells of a microtiter plate coated with either TSP or collagen and which had been previously treated for 1.5 h with either 50 Ml ofa 500-Mg/ml mouse IgG solution in PBS containing 1% BSA (designated IgG) or 50 yd of a 500-tg/ml monoclonal anti-TSP antibody solution in PBS containing 1% BSA (designated anti-TSP). The number of adherent platelets were determined by protein assay as described in Methods. Note: Monoclonal anti-TSP inhibited platelet adhesion to TSP-coated wells, but had no effect on platelet adhesion to collagen-coated wells.
TSP-induced adhesion of normal and Glanzman's thrombasthenic platelets. To further establish that GPIIb-IIIa and VLA-2 are functioning as TSP adhesion receptors, TSP-induced adhesion of thrombasthenic platelets was studied. Platelets from two patients with Glanzman's thrombasthenia were obtained. These patients have been extensively studied by us (16) and others (17) and their platelets have been shown to aggregate only weakly in response to ADP or thrombin, bind < 10% of the fibrinogen of normal platelets, and contain < 10% of the GPIIb-IIIa found in normal platelets. We found that platelets from two thrombasthenic patients adhered to TSP 40-50% as well as normal platelets (Fig. 5) . In addition, anti-GPIIb-IIIa (A2A9)-treated normal platelets (Fig. 5, solid bars) adhered to TSP approximately to the same extent as thrombasthenic platelets (Fig. 5, open bars) or anti-GPIIb-IIIatreated thrombasthenic platelets (Fig. 5, solid bars) . As expected since thrombasthenic platelets are deficient in GPIIb- II1a, anti-GPIIb-IIIa monoclonals had no effect on TSP-induced adhesion of thrombasthenic platelets.
Since two monoclonal antibodies against VLA-2 inhibited TSP-induced adhesion ofnormal platelets (Table V, Fig. 4) , we assessed the effect of one ofthese antibodies (6F1 ) on TSP, FN, and collagen-induced adhesion of normal and thrombasthenic platelets (Fig. 6 ). Antibody 6F1 inhibited by > 90% TSP and collagen-induced adhesion of normal (Fig. 6 , open bars) and thrombasthenic platelets (Fig. 6, solid bars) . In contrast, 6F1 had no effect on adhesion of normal platelets to fibronectin, but inhibited fibronectin-dependent adhesion of thrombasthenic platelets.
These results support the conclusion that TSP-induced platelet adhesion is partly mediated through the platelet fibrinogen receptor-GPIIb-IIIa complex, and the putative platelet collagen receptor, VLA-2. Furthermore, since thrombasthenic platelet adhesion to fibronectin was also inhibited by anti-VLA-2, it appears that the VLA-2 complex functions as a fibronectin receptor in thrombasthenic platelets.
Discussion
TSP is a 450-D platelet-secreted protein composed of three identical disulfide-linked polypeptide chains (18) . Under the electron microscope, the TSP polypeptide appears as long flexible chains with globular ends (19) . TSP specifically interacts with a variety of macromolecules including heparin (20) body and evaluated for adhesion to either TSP (designated TSP), fibronectin (designated FN), or collagen (designated Coll). The number of adherent platelets were determined by protein assay. Note: 6F1 inhibited adhesion of thrombasthenic platelets to TSP, fibronectin, and collagen, whereas 6F1 inhibited adhesion of normal platelets to TSP and collagen but not to fibronectin.
brinogen (5), fibronectin (21), collagen (22) , plasma proteins (23) , and lipids (24) . Like fibronectin, TSP possesses linear polypeptide domains that recognize heparin (25) , fibrinogen (26), and collagen (27) .
It is generally accepted that TSP plays a major role in mechanisms ofcell-cell cohesion and cell-substratum adhesion. For example, TSP promotes platelet aggregation (4), plateletmonocyte interaction (28) and the cell substratum adhesion of a variety of cells including fibroblasts and endothelial cells (6) , melanoma cells (29) , squamous carcinoma cells (30) , karatinocytes (31), and osteoblasts (32) . In addition, TSP has been shown to destabilize endothelial cell-fibronectin contacts and therefore modulate cell-substratum adhesion (33) .
The studies described above establish a role for TSP in cellsubstratum adhesion. However, it is not clear what role, if any, TSP plays in mechanisms ofplatelet adhesion. Previous studies have yielded conflicting results. For example, an early report by Lahav et al. (34) suggested a role for TSP in platelet adhesion. These investigators showed that TSP became cross-linked to either fibronectin or collagen, derivatized with a photoactivatable crosslinking agent, when platelets were allowed to adhere to these derivatized substrates immobilized on glass. Later, Lahav (35) published a report showing that glass and protein-covered surfaces when treated with TSP lose their capacity to bind unstimulated platelets. Similarly, Houdijk et al. (36) concluded that TSP played no role in subendothelial platelet interactions based on the observation that anti-TSP antibodies failed to block platelet adhesion to endothelial matrix when citrated blood was perfused over the matrix material under conditions of both low and high shear rate. In contrast, Adams and Hallee (37) demonstrated that TSP promoted platelet adhesion when red cells and platelets were perfused over TSPcovered plastic and glass surfaces at a shear rate of 100 s-' (37) .
Finally, Young et al. (38) clearly showed that platelets adhered and spread and fibrin was deposited on canine femoral arteriovenous shunts coated with human TSP and in contact with the circulating blood for 15 min.
The studies presented in this report support the hypothesis that TSP plays a role in cell-substratum adhesion. We observed that unactivated platelets specifically adhered to TSPcoated surfaces. The adhesion was divalent cation specific.
Mn+2 ion was the most effective in promoting TSP-induced platelet adhesion. A similar Mn"2 effect on TSP-induced cell adhesion has recently been reported for a variety oftumor cells including human melanoma cells (39) . Other divalent ions tested, Ca+2 and Mg+2, promoted platelet adhesion but to a much lesser extent than Mn+2. Fibronectin-induced platelet adhesion showed a similar ion dependence to that of TSP except that both Ca+2 and Mg+2 promoted more adhesion to fibronectin. In contrast, all three ions tested promoted approximately the amount of platelet adhesion to fibrinogen. These results suggest that platelet adhesion to various platelet adhesive proteins proceed by mechanisms requiring different ion specificities. Since the serum concentrations of Mnt2 have been reported to be in the range of 0.154-0.736 MM (40) , it is possible that Mn+2 may promote the Ca+2-and Mg+2-dependent TSP-induced platelet adhesion in blood. Failure of Lahav (35) and Houdijk et al. (36) to observe significant TSP-dependent platelet adhesion could be due to the low affinities of platelets for TSP in the presence of Ca+2 and Mg+2 and Houdijk's use of citrated blood which would be expected to reduce the divalent ion concentration required to promote TSP-dependent platelet adhesion. The observation by Santoro (41) that only activated platelets adhere to TSP is difficult to reconcile with our observations since activated platelets in our experience adhere nonspecifically to BSA-coated surfaces. Furthermore, unactivated platelets would be expected to adhere to TSP, since Wolf et al. (42) found that unactivated platelets possessed 3,100 binding sites for TSP with affinities five times more favorable than for activated platelets. The identity of the platelet receptor mediating TSP-dependent platelet-adhesive interactions was of great interest to us because we had previously speculated on the possibility that GPIIb-IIIa functions as a TSP platelet receptor based on our observation that TSP binds GPIIb-IIIa in vitro (14) . The specific functional consequence of this binding interaction, however, remains unclear since GPIIb-IIIa has been shown to interact with a number of platelet adhesive proteins, notably fibrinogen (44) . In addition, several TSP-binding proteins have been reported in the literature which function in some capacity as either mediators ofcell cohesion or cell adhesion. For example, endothelial cells (45) and melanoma cells (46) have a vitronectin-like receptor that functions in TSP-induced adhesion. Platelets also possess the same vitronectin-like receptor which binds TSP in vitro (47) but the function ofthis receptor in the platelet system is not yet known. Finally, platelet GPIV has been called the platelet TSP receptor because GPIV binds TSP in vitro (48) and mediates platelet-monocyte interaction (28), which is TSP dependent.
To identify the TSP adhesion receptor in our system, we assessed the antiadhesive activity of a number of monoclonal antibodies specific against platelet glycoproteins likely to function as TSP binding proteins. These antibodies were specific against GPIb, GPIV, the vitronectin receptor, GPIIIa, GPIIbMIIa, and VLA-2. Only antibodies against platelet integrins, GPIIb-IIIa and VLA-2, blocked TSP-induced platelet adhesion. Anti-GPIIb-IIIa antibodies blocked 50-60% adhesion at saturating antibody concentrations, whereas anti-VLA-2 antibodies showed nearly total inhibition at antibody concentrations as low as 5-10 ,ug/ml, suggesting that both GPIIb-IIIa and VLA-2 mediate TSP-induced platelet adhesion. This conclusion was further supported by the observation that thrombasthenic platelets, which are essentially deficient in GPIIb-IIIa, adhered to TSP to the same extent as anti-GPIIb-IIIa-treated normal platelets, which have their GPIIb-IIIa membrane sites blocked with antibody and behave functionally like thrombasthenic platelets. Furthermore, in contrast to anti-GPIIbIlIa, anti-VLA-2 monoclonal antibodies totally blocked TSPinduced adhesion of normal and thrombasthenic platelets. Anti-VLA-2 antibodies also blocked collagen-induced adhesion of normal and thrombasthenic platelets, suggesting that collagen and TSP share the same receptor on normal and thrombasthenic platelets. Interestingly, anti-VLA-2 had no effect on fibronectin-induced adhesion of normal platelets but inhibited fibronectin adhesion of thrombasthenic platelets. A possible explanation for this observation might be that thrombasthenic platelets which lack GPIIb-IIIa, a protein that functions both as fibrinogen and fibronectin receptor in platelets (49) , are able to use VLA-2 as their fibronectin receptor. Taken together, these data suggest that both GPIIb-IIIa and VLA-2 function as receptors for TSP-induced platelet adhesion.
Finally, our data raise the possibility that TSP may not only play a direct role in platelet adhesion but also participate in platelet-collagen interactions. Our data may help to explain the hemorrhagic diathesis of a patient that suffered a bleeding tendency, characterized by frequent petechial bleeding, postoperative hemorrhages, and severe menstrual bleeding episodes, necessitating blood transfusions (2) . The patient had a long bleeding time, abnormal collagen-induced adhesion, and defective collagen-induced aggregation, but normal ADP-induced aggregation. Analysis of her platelets revealed the absence of VLA-2 and intact TSP. TSP corrected the aggregation defect and, when TSP and VLA-2 appeared in her platelets after menopause, her bleeding tendency disappeared. One explanation for these patient data, as supported by the results of this study, is that TSP can bind either GPIIb-IIIa or VLA-2 and promote collagen-induced aggregation and adhesion by providing a platelet collagen binding site, since TSP interacts strongly with collagen (22) . These data raise the fascinating possibility that TSP may function in blood to promote platelet collagen adhesion at low sheer rate while von Willebrand factor is active at high sheer rates.
